Olivia Vizier

360 DX

With Updated FDA Clearance, Digital Pathology Firm PathAI Eyes Expansion

With marketing clearance from the US Food and Drug Administration that reduces the time to validate the use of its software with new hardware, digital pathology firm PathAI said that it plans to expand its reach by giving customers flexibility in the design of their lab systems and future-proofing its technology.

With Updated FDA Clearance, Digital Pathology Firm PathAI Eyes Expansion Read More »

Biotech TV

RBC Global Healthcare Conference: Ahead of an important trial readout next month, Jeff Stein explains Cidara’s unique approach to influenza and how it differs from vaccines

He describes the science behind Cidara’s Cloudbreak Drug-Fc conjugates, which might have uniform efficacy regardless of how the flu changes each season. Plus, a preview of next month’s readout, and how FDA discussions around this have been.

RBC Global Healthcare Conference: Ahead of an important trial readout next month, Jeff Stein explains Cidara’s unique approach to influenza and how it differs from vaccines Read More »

CheckRare

CAMP4 Therapeutics’ Programs For Urea Cycle Disorders and SYNGAP1

CAMP4 is currently working on CMP-CPS-001, a novel investigational therapy designed to address the underlying cause of urea cycle disorders (UCDs) by regulating genes associated with the condition. The first clinical trial of this program was initiated in March 2024 with a phase 1 single-ascending dose study in healthy volunteers. Following the completion of this

CAMP4 Therapeutics’ Programs For Urea Cycle Disorders and SYNGAP1 Read More »

CheckRare

Urea Cycle Disorders: Overview and Developing Novel Therapies

CAMP4 is currently working on CMP-CPS-001, a novel investigational therapy designed to address the underlying cause of UCDs by regulating genes associated with the condition. The first clinical trial of this program was initiated in March 2024 with a phase 1 single-ascending dose study in healthy volunteers. Following the completion of this trial, a multiple-ascending

Urea Cycle Disorders: Overview and Developing Novel Therapies Read More »

Science News

Humans have shockingly few ways to treat fungal infections

Rex’s company, F2G, is in the final stages of clinical trials for an antifungal drug called olorofim. This drug prevents fungi from making pyrimidines, a type of building block for DNA and RNA. Interfering in that process prevents fungi from replicating and can kill some dangerous fungi, including Aspergillus species. If the drug is approved

Humans have shockingly few ways to treat fungal infections Read More »